10-Q quarterly report · filed Nov 6, 2026

Bio-Techne (TECH) Q3 2026 10-Q Quarterly Report

Short answer

Bio-Techne (TECH) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $300M (up 4.6% year over year) with net income of $28M.

Q3 2026 key financials · XBRL

Revenue
$300M
+4.6% YoY
Net income
$28M
−25.9% YoY
Operating margin
12.2%
Gross margin
65.6%
EPS (diluted)
$0.18
−25.0% YoY

Source: XBRL data from the Bio-Techne (TECH) Q3 2026 10-Q on SEC EDGAR. USD.

Bio-Techne Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $299.7M, up 5% YoY from $286.6M
  • Gross margin 65.6% vs 65.6% YoY, adjusted margin 69.3% vs 70.2%
  • Protein Sciences best performer: sales $219.7M, up 9%; operating margin 37.9% vs 38.4%
  • Diagnostics and Spatial Biology weakest: sales $80.2M, up 1%; operating margin 7.4% vs 11.2%
  • Cash $350.0M vs $264.7M; operating cash flow $73.1M vs $27.6M, capital expenditures $5.9M and $12.6M dividends

Risk Factors

  • No material changes to previously disclosed risk factors during the quarter ended September 30, 2026
  • Carried-forward risks include macroeconomic conditions affecting demand and operating results
  • Carried-forward risks include competition and technological change in life-science markets
  • Carried-forward risks include liquidity, debt, and foreign-currency exposure

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Bio-Techne quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.